NN102 SPRINT-MS top-line results achieve primary endpoints

MediciNova, the industry sponsor of NN102 SPRINT-MS, announced the positive top-line results from the trial. The second funded NeuroNEXT trial, a study to evaluate the activity, safety, and tolerability of Ibudilast in patients with Multiple Sclerosis (MS), has very promising results for MS treatment. Results indicate that Ibudilast demonstrated a statistically significant reduction in the rate of progression of whole brain atrophy as compared to placebo.

External Source: 
Related Project: